{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:37:48Z","timestamp":1789562268938,"version":"build-2803163510"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T21:20:38Z","timestamp":1652822438000},"page":"442-451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["RESIRT: A Phase 1 Study of Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres in Patients With Primary Renal Cell Carcinoma"],"prefix":"10.1016","volume":"20","author":[{"given":"Paul L.","family":"de Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Aslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy","family":"Nour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"de Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.05.006_bib0001","unstructured":"Globocan. The Global Cancer Observatory. Kidney Fact Sheet; 2020."},{"key":"10.1016\/j.clgc.2022.05.006_bib0002","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Version 4.2022. 2021 [cited 2022 18 January]; Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf (Access date: 18 January 2022)."},{"key":"10.1016\/j.clgc.2022.05.006_bib0003","unstructured":"Ljungberg B, Albiges L, Bedke J, et\u00a0al. Guidelines on Renal Cell Carcinoma: EAU; 2021 (Access date: 18 January 2022)."},{"key":"10.1016\/j.clgc.2022.05.006_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2022.05.006_bib0005","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1080\/02841860802123196","article-title":"Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney","volume":"47","author":"Svedman","year":"2008","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0006","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","article-title":"A prospective Phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma","volume":"45","author":"Svedman","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.juro.2010.09.001","article-title":"Super selective radio embolization of the porcine kidney with 90yttrium resin microspheres: a feasibility, safety and dose ranging study","volume":"185","author":"MacKie","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0008","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00270-016-1482-3","article-title":"Histological comparison of kidney tissue following radioembolization with yttrium-90 resin microspheres and embolization with bland microspheres","volume":"39","author":"de Silva","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0009","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.clgc.2022.05.006_bib0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1477-7525-5-34","article-title":"Symptom burden among patients with renal cell carcinoma (RCC): content for a symptom index","volume":"5","author":"Harding","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clgc.2022.05.006_bib0011","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1089\/end.2013.0498","article-title":"Can RENAL and PADUA nephrometry indices predict complications of laparoscopic cryoablation for clinical stage T1 renal tumors?","volume":"28","author":"Lagerveld","year":"2014","journal-title":"J Endourol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0012","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/j.1464-410X.2012.11432.x","article-title":"Percutaneous cryoablation of renal masses: Washington University experience of treating 129 tumours","volume":"111","author":"Kim","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.05.006_bib0013","doi-asserted-by":"crossref","first-page":"E737","DOI":"10.1111\/j.1464-410X.2012.11550.x","article-title":"A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma","volume":"110","author":"Siva","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2022.05.006_bib0014","first-page":"104","article-title":"Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?","volume":"18","author":"Ruhle","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jfma.2015.05.003","article-title":"Natural history of renal cell carcinoma: An immunohistochemical analysis of growth rate in patients with delayed treatment","volume":"115","author":"Zhang","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.clgc.2022.05.006_bib0016","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1464-410X.2007.06811.x","article-title":"The natural history of untreated renal masses","volume":"99","author":"Crispen","year":"2007","journal-title":"BJU Int"},{"issue":"Suppl. 15","key":"10.1016\/j.clgc.2022.05.006_bib0017","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1200\/JCO.2020.38.15_suppl.4590","article-title":"A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678","volume":"38","author":"Tai","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.05.006_bib0018","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1634\/theoncologist.2019-0924","article-title":"A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases","volume":"25","author":"Wang","year":"2020","journal-title":"Oncologist"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322001112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:35:54Z","timestamp":1761564954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322001112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322001112"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.05.006","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RESIRT: A Phase 1 Study of Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres in Patients With Primary Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}